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The apical membrane antigen 1 (AMA1), merozoite surface antigen 2 (MSA2), and merozoite surface protein
1 (MSP1) are asexual-stage proteins currently being evaluated for inclusion in a vaccine for Plasmodium
falciparum. Accordingly, it is important to understand factors that control antibody responses to these anti-
gens. Antibody levels in plasma from residents of Etoa, Cameroon, between the ages of 5 and 70 years, were
determined using recombinant AMA1, MSA2, and the N-terminal region of MSP1 (MSP1-190L). In addition,
antibody responses to four variants of the C-terminal region of MSP1 (MSP119) were assessed. Results showed
that all individuals produced antibodies to AMA1, MSA2, and MSP1-190L; however, a proportion of individ-
uals never produced antibodies to the MSP119 variants, although the percentage of nonresponders decreased
with age. The influence of age and human leukocyte antigen (HLA)-DRB1/DQB1 alleles on antibody levels was
evaluated using two-way analysis of variance. Age was correlated with levels of antibodies to AMA1 and MSP119
but not with levels of antibodies to MSA2 and MSP1-190L. No association was found between a single HLA
allele and levels of antibodies to MSA2, MSP1-190L, or any of the MSP119 variants. However, individuals
positive for DRB1*1201 had higher levels of antibodies to the variant of recombinant AMA1 tested than did
individuals of all other HLA types. Since the effect was seen across all age groups, HLA influenced the level but
not the rate of antibody acquisition. This association for AMA1, combined with the previously reported
association between HLA class II alleles and levels of antibodies to rhoptry-associated protein 1 (RAP1) and
RAP2, indicates that HLA influences the levels of antibodies to three of the five vaccine candidate antigens that
we have evaluated.
Malaria, caused by Plasmodium falciparum, is a major public
health problem in the world, killing greater than 1 million
individuals each year (43). The erythrocyte stage of the P.
falciparum parasite is the stage that causes clinical disease (7).
Immunity to this stage develops following repeated clinical and
subclinical infections, suggesting that it may be possible to
develop a vaccine for malaria. Several erythrocyte-stage mol-
ecules are currently being considered for vaccine development.
Among these are the apical membrane antigen 1 (AMA1), the
merozoite surface antigen 2 (MSA2), and the merozoite sur-
face protein 1 (MSP1) (35). All of these antigens are expressed
on the surface of merozoites (18) and, thus, are accessible to
antibody and effector cells. AMA1 is a polymorphic protein
that is localized to the apical region in late schizonts and free
merozoites (30). Initially, AMA1 is synthesized as an 83-kDa
molecule that rapidly undergoes N-terminal processing to a
66-kDa form (19). Around the time of schizont rupture, it is
thought that the processed form is transported to the merozo-
ite surface (30). MSA2 is a highly polymorphic merozoite sur-
face protein of 40 to 50 kDa that consists of conserved carbox-
yl- and amino-terminal regions flanking a central variable
region composed of both repetitive and nonrepetitive se-
quences (37, 42). MSP1 is a polymorphic glycoprotein of ap-
proximately 195 kDa that is the major surface antigen of the
invasive merozoite stage (18). Posttranslational processing of
MSP1 at the time of schizont rupture generates multiple frag-
ments that are displayed on the surface of the mature mero-
zoite (4, 17). One of these proteins is the 19-kDa C-terminal
fragment (MSP119). Recombinant protein MSP1-190L, located
at the N terminus of MSP1, contains 175 amino acids of blocks
3 and 4 (15).
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All three antigens are reported to be targets of parasite
invasion-inhibitory or growth-inhibitory antibodies (4, 8, 10,
11, 16, 31, 32, 50). High-titer antibodies to MSA2 and MSP1
have been associated with fewer clinical malaria episodes and
lower prevalences of anemia and/or parasite densities (1, 2, 5,
9, 27, 38, 49, 52). Because all three asexual-stage molecules are
candidates for vaccine development, it is important to under-
stand the factors that control the antibody response to them.
Human leukocyte antigen (HLA) class II alleles are known to
influence antibody production (13). In fact, the genes that
encode class II alleles were originally identified as immune
response genes because of their influence on antibody levels
(26). It has been reported that specific HLA-DR and -DQ
alleles influence levels of antibodies to rhoptry-associated pro-
tein 1 (RAP1) and RAP2 (23). Other investigators have re-
ported an association between an HLA class II allele and the
acquisition of antibodies to a B-cell epitope in the ring-eryth-
rocyte-stage antigen (RESA) (38), the subunit vaccine antigen
SPf66 (3), and a malaria sporozoite antigen (44). Although
field studies showed no influence of HLA on the acquisition of
antibodies to the circumsporozoite protein repeat region (6,
14, 39), a strong influence of HLA-DR on responsiveness to
circumsporozoite protein was observed in phase I vaccine trials
(28).
In the study reported here, we evaluated the influence of
HLA-DRB1 and -DQB1 allelic products on the level and rate
of acquisition of antibodies to recombinant AMA1 (rAMA1),
rMSA2, and rMSP1 (MSP1-190L and four variants of MSP119)
using plasma collected in a cross-sectional study of Cameroon-
ian individuals between the ages of 5 and 70 years. Results
show that, in addition to the previously reported influence of
HLA on levels of antibodies to RAP1 and RAP2 (23), HLA
class II allelic products influence the level of antibodies to the
variant of rAMA1 tested. No HLA influence was observed for
the variant of MSA2 and MSP1-190L tested or for any of the
MSP119 variants used in the study.
MATERIALS AND METHODS
Study design. In 1995, a cross-sectional study was conducted in the rural village
of Etoa, Cameroon. Etoa is a village of 485 individuals where P. falciparum
malaria is holoendemic (36). Malaria transmission is perennial with an estimated
2.4 infectious bites per night during each of the two rainy seasons and 0.4
infectious bites per night during the two dry seasons (36). Previous studies
demonstrated that the prevalence of P. falciparum was 65% in children 5 to 10
years, 34% in adolescents 11 to 15 years, and 29% in individuals over 15 years of
age. Peripheral blood samples were obtained from 200 volunteers representing
146 households. The overall average number of individuals per household in the
entire sample was less than 2. The majority of individuals studied (79.6%) were
single representatives of 116 different households. Of the remaining volunteers,
most (12.2%) came from households represented by two individuals, and those
household members who volunteered often were related by marriage only. The
age distribution for the total sample was as follows: age 5 to 9 years, n  31; 10
to 14 years, n  59; 15 to 29 years, n  44; 30 to 44 years, n  23; 45 years, n
 43. Children less than 5 years of age were not included in the study design.
Plasma samples were assayed for antibodies to rAMA1, MSA2, and MSP1
(MSP1-190L and four MSP119 variants). The project was approved by the Insti-
tutional Review Board of Georgetown University and the Ministry of Health,
Cameroon.
Determination of HLA alleles. DNA was isolated from whole blood drawn in
EDTA by using the Puregene DNA isolation kit (Gentra Systems Inc., Minne-
apolis, Minn.). Allele level typing was performed for HLA-DRB1 and -DQB1
(except for DRB1*04 and DQB1*02) with commercially available kits for me-
dium-level and group-specific resolution (Lifecodes Corporation, Stamford,
Conn.) according to the Lifecodes protocol. In addition, because of the high
occurrence of DR52 group alleles in the Cameroonian population (33), ambig-
uous combinations of DR52-associated DRB1 alleles were resolved using DR52
group-specific primer sets that employed two reverse primers specific for the
Val-Gly polymorphism at amino acid 86 of DRB1 (41). The amplified products
were spotted on membranes and probed with the set of DR52 group-specific
probes from Lifecodes according to the Lifecodes protocol. The following alleles
could be resolved with the sets of primers and probes used: DRB1*0101 to -0104,
*1501 to -1506, *1601 to -1608, *03011 to -0309, *04, *0701, *0801 to -0816,
*0901, *1001, *1101 to -1126, *1201 to -1205, *1301 to -1315, *1317 to -1327, and
*1401 to -1425 and DQB1*02, *0301 to -0305, *0501 to -0504, *0601 to -0608,
and *0401 and *0402.
rAMA1, rMSA2, and rMSP1. (i) rAMA1. The AMA1 protein was derived from
the full-length Pf83/AMA1 (including putative signal peptide) of the 7G8 strain
(rPF83-7G8-1). The protein was produced in a baculovirus expression system
and was purified using high-performance ion-exchange chromatography in which
elution conditions were defined by charge and hydrophobicity (29). This recom-
binant protein was used to induce antibodies that inhibited parasite invasion in
vitro, and from these a conformation-dependent monoclonal antibody (MAb)
(4G2) was isolated (25).
(ii) rMSA2. The MSA2 protein used has the near-full-length sequence of the
3D7 parasite clone and a molecular mass of 25 kDa, consisting of 250 amino
acids, i.e., 229 of the central domain and 21 of leader and C-terminal sequences
[MRGS(H6)GSV and DLQPSLIS, respectively] (40, 47). MSA2 was expressed in
Escherichia coli and purified by nickel chelate chromatography with nitrilotri-
acetic acid resin (Qiagen, Inc., Valencia, Calif.) followed by reverse-phase and
ion-exchange chromatography (40, 46).
(iii) rMSP1. Two regions of the MSP1 protein were used, four variants of the
19-kDa C-terminal MSP119 fragment and the N-terminal MSP1-190L fragment.
The four MSP119 variants (Q-KNG [FVO-Q], E-KNG [FVO-E], Q-TSR [3D7-
Q], and E-TSR [3D7-E]) were expressed in Saccharomyces cerevisiae and purified
as described previously (24). MSP1-190L consists of a 175-amino-acid fragment
of blocks 3 and 4 derived from the K1 line, fused to the CST3 T-cell epitope from
the P. falciparum circumsporozoite protein (15). The MSP1-190L protein was
expressed in E. coli and purified by nickel chelate chromatography with nitrilo-
triacetic acid resin (Qiagen) followed by ion-exchange chromatography (40).
ELISA. Plasma samples were tested by enzyme-linked immunosorbent assay
(ELISA) for the presence of immunoglobulin G (IgG) antibodies to AMA1,
MSA2, MSP1-190L, and MSP119 variants according to previously described
procedures (20, 24, 34, 45, 51). ELISAs were performed at three different points
in time, and the number of serum samples available for testing differed slightly
(AMA1, n  188; MSA2 and MSP1-190L, n  136; and MSP119 variants, n 
187). Positive and negative controls were included on every plate. For negative
controls, plasma samples collected from 30 nonexposed American Caucasians
(ELISAs with MSA2, MSP1-190L, and MSP119 variants) or from 45 nonexposed
European Caucasians (ELISAs with AMA1) with no history of malaria were
used. A test sample was considered positive if it had an optical density (OD)
greater than twice the standard deviation (SD) of the geometric mean OD of the
negative-control samples. The positive-control samples consisted of a pool of
plasma collected from adult individuals living in an area of holoendemicity of
Ivory Coast or Cameroon; rabbit antisera raised against recombinant proteins
(for MSA2 and MSP1); rat MAb 28G2dcl, which recognizes the C-terminal
region of AMA1 (51); and murine MAbs to rMSA2 (40), and rMSP1 (8, 20).
Results are given without background subtracted. During the optimization and
standardization of each ELISA, conditions were extensively tested to control for
nonspecific binding and to ensure that the measured human antibody responses
were specific for each antigen. Endpoint titrations of immune sera with high and
low ODs were performed for each antigen to ensure that the single serum
dilution selected for measurement would produce an OD that correlated with
antibody titer.
For detection of antibodies to AMA1, high protein-binding microtiter ELISA
plates (Greiner, Laborchnik, Solingen, Germany) were coated with recombinant
Pf83/AMA1 (75 ng/ml in 50 l of phosphate-buffered saline [PBS], pH 8.0, plus
0.02% azide) overnight at 4°C in a humidified chamber (51). Plates were blocked
with 3% bovine serum albumin (BSA) in PBS. Test and control samples were
diluted 1:200 in 0.5% BSA in PBS (pH 8.0), and 100 l was added to duplicate
antigen-coated wells. Alkaline phosphatase-conjugated goat anti-human IgG
(heavy plus light chains) (Pierce, Rockford, Ill.) was used as the secondary
antibody. Bound antibody was detected by adding 50 l of enzyme substrate
(p-nitrophenyl phosphate; Sigma, St. Louis, Mo.)/well at 1 mg/ml in 1 M dieth-
anolamine–0.5 M MgCl2 (pH 9.8), incubating the plates for 30 min at room
temperature in the dark, and then reading them at 405 nm. A serum sample was
considered positive if the value was 0.2 OD units (i.e., greater than the mean
OD  2 SDs of the negative-control plasma).
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For detection of antibodies to MSA2 and MSP1-190L, microtiter ELISA
plates (Immunoplate [Maxisorb]; Nunc) were coated with 50 ng of MSA2 or
MSP1-190L/well in 50 l of coating buffer (15 mM Na2CO3, 35 mM NaHCO3,
pH 9.6) overnight at 4°C (45). Plates were blocked with 1% BSA in PBS, pH 7.4.
Test and control samples were diluted 1:200 in 0.05% Tween 20 and 1% BSA in
PBS, and 100 l was added in triplicate to antigen-coated wells. Peroxidase-
conjugated goat anti-human IgG (gamma chain specific) (Bio-Rad Laboratories,
Hercules, Calif.) was used as a secondary antibody. Bound antibody was detected
with the enzyme substrate o-phenylenediamine dihydrochloride (Pharmacia/Am-
ersham, Piscataway, N.J.) and read at 450 nm. A serum sample was considered
positive if the value was 0.2 OD units (i.e., greater than the mean OD  2 SDs
of the negative-control plasma).
For detection of antibodies to the four MSP119 variants, microtiter ELISA
plates (Immunoplate [Maxisorb]) were coated with 50 ng of MSP119 antigen/well
for each of the four alleles in 100 l of coating buffer overnight at 4°C (20). Plates
were blocked with 1% BSA in PBS, pH 7.4. Test and control samples were
diluted 1:100 in 1% BSA–0.5% normal yeast extract (Difco)–0.05% Tween 20 in
PBS and added to duplicate antigen-coated wells. The secondary antibody was
alkaline phosphatase-conjugated goat anti-human IgG (Kirkegaard & Perry Lab-
oratories, Gaithersburg, Md.). Bound antibody was detected by adding 50 l of
enzyme substrate (p-nitrophenyl phosphate; Sigma)/well at 1 mg/ml in 1 M
diethanolamine–0.5 M MgCl2 (pH 9.8), incubating the plates for 30 min at room
temperature in the dark, and then reading them at 405 nm. A serum sample was
considered positive if the value was 0.4 OD units (i.e., greater than the mean
OD  2 SDs of the negative-control plasma).
Detection of sickle cell trait. Hemoglobin polymorphisms were determined by
electrophoresis with a commercially available kit (Helena Laboratories, Beau-
mont, Tex.).
Statistical methods. The statistical analyses were done using the SAS (SAS
Institute Inc., Cary, N.C.) package. First, analyses were done to determine
whether age or presence of the sickle cell allele accounted for a significant
proportion of the variability in antibody level, i.e., Spearman correlation coeffi-
cients between OD to a recombinant antigen and age were calculated as a
preliminary analysis. Analysis of variance was done to determine whether the
presence of the sickle cell allele (AS) was associated with a change in mean OD
to each of the recombinant malaria antigens. Any variable(s) showing a signifi-
cant association with a change in mean OD was included in the analysis of the
OD association with HLA. For those recombinant antigens for which the OD
value showed a significant correlation with age, the linear relationship was
investigated and determined not to be linear. The variability in OD associated
with age was best accounted for by dichotomizing with respect to individuals
under age 15 versus those age 15 or greater, with the exception of RAP2. In the
case of RAP2, the difference in OD was observed between those less than age 30
and those age 30 or greater.
Multiway (“multiallele”) and two-way (“single-allele”) analyses of variance
were used to determine the effect of HLA on antibody levels. In the multiallele
analyses, age group (15 years versus 15 years) was one factor and the HLA
alleles at a given locus were the other factors. Only those HLA-DRB1 and
-DQB1 alleles that were present in at least 20 individuals in the total sample of
Cameroonians were considered. As a result, seven DRB1 alleles and five DQB1
alleles were included in the analysis. These alleles are referred to hereafter as
“frequent” alleles. To test for a locus effect, the multiallele analysis of variance
used all the frequent alleles at a given locus as the factors. In the single-allele
analyses, age group was one factor and a single HLA allele was the second factor.
In each case, the dependent variable was the antibody level (i.e., OD value), a
quantitative value.
To rule out any HLA association possibly due to common household environ-
mental conditions or genetics, associations were reanalyzed using a subsample
that consisted of only one individual from each of the 146 distinct households.
From the 30 households with more than one member in the study, an individual
who was less than 15 years of age and/or was positive for the HLA allele of
interest (i.e., the allele associated with high mean OD for the recombinant
antigen of interest) was chosen. Data were tested by nonparametric analysis (i.e.,
Wilcoxon rank sum test comparing age-adjusted values of those individuals
positive for the HLA allele with those negative for the allele).
In the first pass, the effect of variance in OD due to frequent HLA alleles at
each locus was evaluated. Thus, the general hypothesis of partial association
between mean OD and presence of the frequent HLA alleles was tested for each
locus separately. The F test of no partial effect of any of the seven frequent
DRB1 alleles on mean OD had df  7 and df  179 [i.e., 188 (n)  1  1 (for
age group) 7 alleles]. Similarly, the F test of no partial effect of presence of any
of the five frequent DQB1 alleles on mean OD had df  5 and df  181. If a
locus showed a significant finding at the 0.10 level, backward elimination of
nonsignificant HLA alleles was performed to determine those alleles that were
significantly associated with the increased antibody level.
Analyses also were performed that allowed for interaction between age and
HLA allele effects. Only results that were consistently significant at the 0.01 level
in the initial screen considering all age-antigen-antibody combinations and that
held up at the 0.05 level in a corresponding analysis of age group-adjusted values
were considered noteworthy.
A Bayesian analysis was performed to determine the optimal subset of pre-
dictors of antibody level for those malaria antigens shown in the “frequentist”
analyses, described above, to be associated with an HLA allele, i.e., AMA1. The
method involved an extension of a method for choosing the optimal subset of
predictors from a set of p candidate independent predictors proposed by George
and McCullough (12). These authors proposed that the presence of a variable j
in the model is a Bernoulli variable, j, and that the prior distribution of the
coefficients, 	j, each in turn depends on j. Markov chain Monte Carlo sampling
methods were used to determine the posterior distribution of the 2p values of the
vector (px1) of the j and to choose, as the final model, that model for which the
posterior probability is largest. Suh et al. (48) extended this approach to the
problem of choosing a combination of m markers from a larger set of n candidate
markers in a linkage analysis of a complex disease. Here, the George and
McCullough (12) method is extended to the analysis of a locus with m candidate
alleles plus one factor (age) to determine the combination of frequent HLA
alleles and age that has the highest posterior probability. Thus, stochastic search
variable selection (SSVS) involved considering a regression model that includes
all p candidate predictors, Y  
  	kXk  ε, ε  N(0, 2), with prior
distribution of the 	 set as 	k  k  (1  k) N(0, 2)  k N(0, c2 2). The prior
for the k is identically Bernoulli with parameter P  1/2, and we consider 	k/,
c)  (1, 5), (1, 10), (10, 100), and (10, 500) where 	k denotes the standard error
(SE) of 	k. For the Etoa data, we applied SSVS to AMA1 by setting Y  AMA1
and considering P  8 predictors of Xi (i  1, 2, . . .7) and X8  Xage.
RESULTS
HLA-DRB1 and -DQB1 allele and haplotype frequencies in
Etoa. HLA-DRB1 and -DQB1 typing was performed on DNA
samples from the total sample of 200 Cameroonians. For the
purpose of analysis with antibody levels, the number of indi-
viduals positive for each allele was determined. Both the num-
ber of individuals positive for the HLA-DRB1 and -DQB1
alleles and the relative frequency of each allele are given in
Table 1. Only those alleles present in at least 20 individuals
(i.e., frequent alleles) were considered in the subsequent anal-
yses of the effect of HLA on antibody level. Of the130 DRB1
alleles assessed, only 17 were detected. Seven DRB1 alleles, in
the order of frequency, were present in at least 20 individuals,
i.e., DRB1*1503, *1301, *0102, *03011, *0701, *1101, and
*1201. HLA-DRB1*08041, *1102, and *1302 were present at
intermediate frequencies (7 to 9%). All other DRB1 alleles,
DRB1*0101, *03021, *0901, *1001, *1202, *1303, and *1401,
were observed at frequencies of 2%. Of the 20 DQB1 alleles
assessed, 13 were detected (Table 1). The five DQB1 alleles
present in at least 20 individuals, in order of frequency, were
DQB1*0602, *02, *0501, *03032, and *0301. DQB1*0605 was
present at an intermediate frequency (7%), while all other
DQB1 alleles were detected at frequencies of 3.5%.
HLA-DR/DQ haplotypes were assigned based on HLA-DR
and -DQ haplotypes determined in a previous Cameroonian
population study that employed a standard maximum likeli-
hood estimation procedure (33). The previous population was
composed, in part, of the same ethnic group as the residents of
Etoa. The frequently determined haplotypes present in Etoa,
in the order of frequency, are listed in Table 2. These were
used for antibody level association analyses.
Production of antibodies to AMA1, MSA2, and MSP1-190L.
Because of the high rate of malaria transmission in Etoa,
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children acquire antibodies to many asexual-stage antigens by
the time they reach 5 years of age (36). Thus, we determined if
the proportion of individuals with antibodies (i.e., percent re-
sponders) to AMA1, MSA2, and MSP1-190L increased with
age. Results showed that all individuals evaluated had antibod-
ies to AMA1, MSA2, and MSP190L by the age of 5 years and
beyond (Fig. 1). That is, all plasma samples had OD values
above the cutoff for positivity, which was OD  0.20. Thus,
there was no evidence of major histocompatibility complex
(MHC) restriction to these antigens in this population.
Next, the effect of age on antibody level (i.e., OD) was
evaluated. Results of Spearman nonparametric correlation
analyses showed a correlation between age and OD level for
AMA1 but not for MSA2 or MSP1-190L. To determine if the
age effect was present across all age groups, median antibody
levels were compared among five age groups (ages 5 to 9, 10 to
14, 15 to 29, 30 to 44, and 45 years) formed so as to have
approximately 20% of the sample in each group. Data are
shown in Fig. 1. As expected, median levels of antibodies to
MSA2 and MSP1-190L did not change with increasing age (P
 0.1). For AMA1, median antibody levels for age groups 5 to
9 and 10 to 14 years (i.e., 15 years) differed significantly from
median antibody levels for age groups 15 to 29, 30 to 44, and
45 years (i.e., 15 years and older) (P  0.05). When the
median level of antibodies to AMA1 was compared between
children 15 years and individuals 15 years and older, a sig-
nificant difference was detected (P  0.03). Thus, levels of
antibodies to AMA1 did not reach maximal levels until age 15
years, but thereafter they did not change.
Production of antibodies to four MSP119 variants. In con-
trast to the above recombinant antigens, not all individuals
produced antibodies to MSP119 C-terminal variants (i.e., a
proportion of the population appears to be nonresponders,
defined by an OD of 0.4) (Fig. 2). The percentage of re-
sponders increased with age but never reached greater than
90%. For example, 37% of children aged 5 to 9 years, 33%
aged 10 to 14 years, 57% aged 15 to 29 years, 64% aged 30 to
44 years, and 69% 45 years or older had antibodies to the
MSP119 variant FVO-E (Fig. 2). The percentage of responders
in different age groups was similar for FVO-Q, 3D7-E, and
3D7-Q. The median level of antibodies to each of the four
MSP119 variants also increased with age (Fig. 2). Comparison
of antibody levels showed that the median OD for age groups
less than 15 years differed significantly from those for age
groups of 15 years and older (P  0.001). This implies that
levels of antibodies to each of the four MSP119 variants, at
least, did not reach maximum until age 15 years, similar to the
level of antibodies to AMA1.
TABLE 1. HLA-DR/DQ allele frequencies in individuals living
in Etoaa
Allele
(2n  400)
No. of individuals
with allele
Relative frequency
(no. of individuals/200)
DRB1b
*0101 2 0.01
*0102 22 0.11
*03011 36 0.18
*03021 3 0.015
*0701 26 0.13
*08041 15 0.075
*0901 3 0.015
*1001 4 0.02
*1101 25 0.125
*1102 13 0.065
*1201 25 0.125
*1202 1 0.005
*1301 68 0.34
*1302 18 0.09
*1303 1 0.005
*1401 2 0.01
*1503 109 0.545
DQB1c
*02xx 67 0.335
*0301 28 0.14
*03032 49 0.245
*0401 1 0.005
*0402 3 0.015
*0501 56 0.28
*0502 1 0.005
*05031 1 0.005
*0602 128 0.64
*0603 1 0.005
*0604 7 0.035
*0605 14 0.07
*0608 2 0.01
a Sample represents total number of individuals in sample (n  200).
b DRB: 27 homozygotes, 173 heterozygotes.
c DQB: 42 homozygotes, 158 heterozygotes.
TABLE 2. Association of frequent HLA-DR/DQ haplotypes in Etoa with antibody levels
HLA-DR/DQ haplotypea
Result for antigen(s)
AMA1 RAP1 RAP2 MSA2, MSP1–190L,and MSP119
DRB1*1503, DQB1*0602 NSb NS NS NS
DRB1*1301, DQB1*03032 NS NS NS NS
DRB1*03011, DQB1*02 NS NS 0.11, SE  0.048,
P  0.020c
NS
DRB1*0701, DQB1*02 NS NS NS NS
DRB1*0102, DQB1*0501 NS NS NS NS
DRB1*1201, DQB1*0501 0.17, SE  0.065,
P  0.009c
NS NS NS
DRB1*1101, DQB1*0602 NS NS NS NS
a Haplotypes are listed in order of frequency.
b NS, nonsignificant (estimated coefficient 0.05, P  0.15).
c Estimated difference in mean OD value between individuals with the indicated haplotype and those without the haplotype, followed by the estimated SE of
difference.
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Correlation analyses were performed among the antibody
responses to the four naturally occurring MSP119 variants
tested in the population of endemicity of Etoa. Correlations
among the responses to all four variants were highly significant
(r  0.85 to 0.98; P  0.0001) (Table 3). The highest correla-
tion was between responses to FVO-E and FVO-Q (r  0.98).
The correlation was slightly lower between responses to 3D7
variants, 3D7-E and 3D7-Q (r  0.90). In fact, the response to
3D7-E showed a higher correlation with those to FVO-E and
FVO-Q than with that to 3D7-Q (r  0.94), the variant with
which it shares the greatest amino acid sequence homology.
Although antibody levels were also highly correlated between
MSP1-190L and the MSP119 variants (P  0.0001), the corre-
lation coefficient between MSP1-190L (N-terminal blocks 3
and 4) and each of the MSP119 variants (C-terminal block) (r
 0.42 to 0.46) was lower than those among the variants (r 
0.85 to 0.98).
Hemoglobin S does not influence levels of antibodies to
AMA1, MSA2, MSP1-190L, or MSP119. Since the sickle cell
trait (AS) provides a protective effect against malaria, the
influence of sickle (AS) versus normal hemoglobin (AA) on
the level of antibodies to AMA1, MSA2, MSP1-190L, and the
four MSP119 variants was evaluated. No significant difference
in levels of antibodies to any of the antigens was observed for
individuals who were AS heterozygotes compared to those who
were AA homozygotes. Therefore, sickle cell trait was not
considered in the analyses of the influence of frequent HLA
alleles on antibody level.
HLA influences levels of antibodies to AMA1 but not to
MSA2, MSP1-190L, or the MSP119 variants. The influences of
HLA-DRB1 and -DQB1 alleles and haplotypes on levels of
antibodies to AMA1, MSA2, MSP1-190L, and the MSP119
variants were analyzed. Since everyone in the population pro-
duced detectable amounts of antibodies to the three recombi-
nant antigens, AMA1, MSA2, and MSP1-190L, restriction to
these antigens did not appear to be a problem. However, since
a proportion of the population appeared to be nonresponders
to MSP119, restriction could have influenced the nonresponder
status.
Multiallele and single-allele regression analyses were used to
evaluate if a given frequent HLA-DR or -DQ allele or fre-
quent HLA-DR/DQ haplotype had an influence on antibody
levels independent of age. That is, did a single HLA allele or
haplotype correlate with higher or lower mean OD values
relative to individuals positive for all other HLA alleles or
haplotypes? The multiallele regression analyses of seven
DRB1 alleles plus age (15 years versus15 years) resulted in
only one new locus-wide partial association (significant at the
0.1 level) between antibody levels and the HLA alleles. This
finding was observed for AMA1 with the DRB1 alleles (F [7,
179]  1.87, P  0.07). Age (15 years versus 15 years) was
a significant factor as well for the AMA1 antibody level (F [1,
179]  14.8, P  0.0001).
Results of the multiallele regression analyses with AMA1
OD values as the dependent variable are shown in Table 4. The
coefficient estimates, their SEs, and the P value associated with
each coefficient are reported. By the use of forced entry of the
seven dummy variable values corresponding to each of the
seven frequent DRB1 antigens, the only antigen showing a
significant partial association with AMA1 antibody levels is
DRB1*1201 (P  0.05). By the use of backward elimination of
the nonsignificant alleles, the final model obtained includes an
increase of AMA1 OD associated with an age of 15 years (P
 0.0001) and a significant increase in AMA1 OD associated
with DRB1*1201 (P  0.05). Table 4 also reports the coeffi-
cient estimates obtained on doing separate, single-allele re-
FIG. 1. Relative levels of antibodies to AMA1, MSA2, and MSP1-
190L, in each of five age groups (5 to 9, 10 to 14, 15 to 29, 30 to 44, and
45 years). Plasma samples from individuals residing in Etoa were
tested by ELISA at a 1:200 dilution. Outlying values are shown as
individual dots. Values above OD  0.2 were considered antibody
positive (i.e., greater than the mean  2 SDs of the negative-control
plasma sample). The OD values for each malarial antigen are dis-
played in box plots, with the median values represented by the hori-
zontal line within each box. The boxed regions represent the inter-
quartile ranges, while the upper and lower vertical bars represent the
90th and 10th percentiles, respectively.
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gressions, their standard errors, and the P value associated
with each coefficient. Single-allele analyses of the frequent
DRB1 alleles with age also showed a significant association
between levels of antibodies to AMA1 and those to
DRB1*1201 (single-allele estimated coefficient  0.177, SE 
0.062, P  0.005). The estimated coefficient was greater and P
value was smaller with single-allele regressions than with mul-
tiallele regressions. The estimated coefficient for age equals
0.17, SE  0.04. This estimated coefficient for age is, coinci-
dentally, the same as that for DRB1*1201 (i.e., estimated co-
efficient  0.18 with SE  0.06).
Similar multiallele and single-allele regression analysis of
AMA1 antibody level with age and the presence of the five
frequent DQB1 alleles resulted in a nonsignificant locus-wide
finding (F [5, 181]  1.45, P  0.2). Additionally, none of the
DQB1 alleles indicated a significant partial association with
AMA1 antibody levels, all having P values of 0.15 or more.
However, single-allele analyses of the DQB1 alleles with age
resulted in DQB1*0501 showing a significant positive associa-
tion (estimated coefficient  0.102, SE  0.041, P  0.03)
(Table 4).
Single-allele analysis of the DQB1 alleles with RAP1 anti-
body level resulted in confirmation of the previously reported
association between RAP1 and DQB1*03 (23). Detailed re-
sults are not given since these analyses are not a replication on
a new or additional sample but rather a replication on an
enriched sample from the same group as the original study.
The multiallele analysis of RAP1 OD with the frequent DQ
locus alleles and age showed, as suspected, significance at the
0.1 level, F (4, 130)  1.76 (0.05  P  0.10). The correspond-
ing statistic for RAP1 antibody level with the seven frequent
DRB1 alleles indicated no decrease in variance associated with
DRB1, F (7, 127)  0.70 (P  0.5). However, as before (23),
FIG. 2. Relative levels of antibodies to four variants of the C-terminal fragment, MSP119, of the asexual-stage antigen MSP1 (variants FVO-E,
FVO-Q, 3D7-E, and 3D7-Q), in each of five age groups (5 to 9, 10 to 14, 15 to 29, 30 to 44, and 45 years). Plasma samples from individuals
residing in Etoa were tested by ELISA at a 1:100 dilution. Values above OD  0.4 were considered antibody positive (i.e., greater than the mean
 2 SDs of the negative-control plasma sample). Values above each age group indicate percent responders. The OD values for each malarial
antigen are displayed in box plots, with the median values represented by the horizontal line within each box. The boxed regions represent the
interquartile ranges, while the upper and lower vertical bars represent the 90th and 10th percentiles, respectively.
TABLE 3. Correlation among antibody responses to
different antigens
Antigen
Pearson correlation coefficienta
MSP119
MSP1–190L MSA2 AMA1
FVO-E FVO-Q 3D7-E 3D7-Q
FVO-E 0.98* 0.94* 0.85* 0.42* 0.34* 0.25***
FVO-Q 0.94* 0.87* 0.45* 0.36* 0.25***
3D7-E 0.90* 0.46* 0.31** 0.26***
3D7-Q 0.46* 0.31** 0.22***
MSP1–190L 0.44* 0.25***
MSA2 0.24***
AMA1
a *, P  0.0001; **, P  0.001  0.0001; ***, P  0.01  0.001.
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significant single-allele findings are observed for RAP1 and the
“supertype” DQB*03 (P  0.0247) with an estimated increase
in OD for RAP1 of 0.077 (SE  0.035) associated with
DQB1*03. The DQB1 supertype includes the alleles
DQB1*0301 and *03032. When regressed separately, multial-
lele regression results showed an increase in mean OD of 0.107
(P  0.056) with DQB1*0301 and an increase in mean OD of
0.078 (P  0.074) with DQB1*03032. Results of single-allele
analyses of DQB1*0301 and *03032 were also nonsignificant, P
 0.11 and P  0.16, respectively. An increase in OD of 0.10
(SE  0.03, P  0.0003) is estimated to be associated with
being aged 15 years or more.
Similarly, the previously reported finding of an association of
RAP2 antibody level with DRB1*03011 (23) was confirmed in
the single-allele analysis. As for RAP1, detailed results are not
given since these analyses are not a replication on a new sam-
ple but rather a replication on an enriched sample from the
same group as the original study. No findings are significant at
the 0.1 level in the locus-wide multiallele analysis of RAP2 for
DRB1, F (7, 127)  0.94, P  0.5, and for DQB1, F (5, 129) 
1.6, 0.1  P  0.25. Results of single-allele analyses showed
that an estimated increase in RAP2 mean OD is 0.114 (SE 
0.05, P  0.0199). Results of analyses with the five frequent
DQB1 alleles showed a significant although weak association
with DQB1*02. The estimated increase in OD as a result of
being DQB1*02 positive is 0.079 (SE  0.039, P  0.047). No
change in RAP2 OD value is observed in comparing those
individuals under age 30 to those who are 30 years of age or
more.
The corresponding statistics for tests for MSA2 indicated no
decrease in variance associated with the DRB1 locus alleles (F
[7, 127]  0.85, P  0.5) or with the DQB1 (F [5, 129]  0.77,
P  0.5). Similarly, strongly nonsignificant findings were ob-
served for MSP1 (i.e., for example, MSP119 variant FVO-E, F
[7, 178]  0.55, P  0.5 with DRB1, and F [5, 180]  0.46, P
 0.5 for DQB1 and for MSP1-190L, F [7, 127] 0.45, P 0.5
with DRB1 and F [5  129]  0.3, P  0.5 with DQB1).
Results of multiallele and single-allele regression evaluation of
frequent HLA-DRB1 and -DQB1 alleles on OD values to the
recombinant antigens, MSA2 and MSP1, are not given since all
findings were strongly nonsignificant.
Multiallele and single-allele analyses of levels of antibodies
to each of the malarial antigens (AMA1, MSA2, and MSP1)
with the seven most frequently observed HLA-DR/DQ haplo-
types revealed no additional significant associations. Data are
summarized in Table 2. The haplotype DRB1*1201/
DQB1*0501 was positively associated with an estimated in-
crease in mean OD for AMA1 of 0.17 (SE 0.065, P 0.009),
and the DRB1*03011, DQB1*02 haplotype was associated
with an increase in mean OD for RAP2 of 0.11 (SE  0.05, P
 0.019). Only one frequent haplotype contained one of the
DQB1*03 supertype alleles, DRB1*1301/DQB1*03032. This
haplotype showed no significant association with antibody level
(estimated coefficient  0.05, SE  0.04, P  0.16).
Bayesian optimal subset analysis does not identify addi-
tional HLA associations for AMA1. The Bayesian optimal sub-
set analyses with the SSVS method were done for AMA1 OD
with the seven most frequent DRB1 alleles plus age group to
determine the optimal subset of predictors of antibody level.
This analysis was done with the objective of obtaining addi-
tional rather than confirmatory information on associations
between the HLA alleles and antibody level. By using SSVS,
DRB1*1201 and age were in the optimal subset with the high-
est posterior probability under three very different sets of prior
distributions for the model parameters.
HLA does not influence the age of acquisition of antibodies
to AMA1. Since children less than 15 years of age have lower
levels of antibodies to AMA1 than do individuals over the age
of 15 years (Fig. 1), we evaluated whether HLA influenced this
difference. Such interactions would occur if an HLA allele had
an effect on individuals less than age 15 but not on individuals
aged 15 or over or, equivalently, if an age effect was dependent
on the HLA allele of the individual. We did two-way analyses
of variance that included tests for interaction between age
group and each of the frequent DRB1 and DQB1 allele on
level of antibodies to any of the recombinant antigens. No
interaction was found between any frequent DRB1 or DQB1
allele and age group and level of antibodies to any of the
recombinant antigens. These results show that the increase in
level of AMA1-specific antibodies observed with age is not
related directly to the HLA alleles possessed by the individual.
Thus, HLA does not appear to influence the rate of acquisition
of antibodies to AMA1. However, with a sample of this size,
the number of individuals in each age group was of sufficient
power to detect only large differences in rates of acquisition
associated with a given HLA allele.
TABLE 4. Results of regression analyses of AMA1 antibody level
on DRB1 and DQB1 allele and agea
HLA allele No. ofindividuals
Multiallele regression Single-alleleregression
Coefficient
(SE) P
Coefficient
(SE) P
DRB1*0102 20 0.030 0.68 0.002 0.95
DRB1*03011 35 0.020 0.73 0.035 0.50
DRB1*0701 25 0.124 (0.067) 0.065 0.088 0.15
DRB1*1101 23 0.073 0.27 0.075 0.2
DRB1*1201 23 0.141 (0.069) 0.05 0.177 (0.062) 0.005
DRB1*1301 66 0.068 0.17 0.048 0.24
DRB1*1503 103 0.032 0.53 0.025 0.55
DQB1*02 64 0.032 0.5 0.003 0.9
DQB1*0301 25 0.050 0.45 0.007 0.9
DQB1*03032 47 0.077 0.15 0.057 0.2
DQB1*0501 52 0.051 0.40 0.102 (0.041) 0.03
DQB1*0602 121 0.072 0.20 0.070 0.10
a All correlations were significant at the level of 0.01 or less. SEs were all
approximately 0.06. Exact values are given where P is 0.1 for the allele indi-
cated. The multiallele regression model is as follows. For DRB1, E (AMA1) 

  	iXi  	15X15. Here Xi  1 if the individual has DRB1 allele i (i 
*0102, *03011, *0701, *1101, *1201, *1301, or *1503) and Xi  0 otherwise and
X15  1 if the individual’s age is 15 or over and X15  0 otherwise. One
multiallele regression model is considered. For DQB1, E (AMA1)  
  	iXi
 	15X15 where Xi  1 if the individual has allele i (i  *02, *0301, *03032,
*0501, or *0602) and Xi  0 otherwise and X15  1 if the individual’s age is 15
years or more and X15  0 otherwise. One multiallele regression model is
considered. The single-allele regression model is as follows. For DRB1, E
(AMA1)  
  	iXi  	15X15 where Xi  1 if the individual has DRB1 allele
i (i  *0102, *03011, *0701, *1101, *1201, *1301, or *1503) and Xi  0 otherwise
and X15  1 if the individual’s age is 15 years or over and X15  0 otherwise.
Seven separate single-allele regression models are considered. For DQB1, E
(AMA1)  
  	iXi  	15X15 where Xi  1 if the individual has DQB1 allele
i (i  *02, *0301, *03032, *0501, or *0602) and Xi  0 otherwise and X15  1
if the individual’s age is 15 years or more and X15  0 otherwise. Five separate
single-allele regression models are considered.
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DISCUSSION
Results reported herein indicate that age influences anti-
body responses to AMA1 and MSP119 and that HLA has a
direct influence on production of antibodies to AMA1 from
the 7G8 strain. In the Cameroonian village of Etoa, where
malaria transmission is intense and perennial, all individuals
produced antibodies to AMA1, MSA2, and MSP1-190L by 5
years of age (Fig. 1). Levels of antibodies to MSA2 and MSP1-
190L remained constant throughout life, suggesting a maximal
response to these antigens very early in life. Levels of antibod-
ies to AMA1 and the MSP119 variants, however, increased
until the age of 15 years and then remained constant thereafter
(Fig. 1 and 2). Thus, the age at which maximal IgG antibody
levels were acquired differed among the antigens, varying from
5 to 15 years of age.
Antibody responses to AMA1, MSA2, and MSP1-190L mol-
ecules were not restricted by HLA, since all individuals, even
children 5 to 9 years of age, tested positive for antibody. No
association with any HLA-DRB1 or -DQB1 allele or HLA-
DR/DQ haplotype, positive or negative, was observed for lev-
els of antibodies to MSA2 or MSP1-190L. However, HLA has
a moderate but significant effect, regardless of age, on levels of
antibodies to the AMA1 polypeptide molecule from the 7G8
strain. Individuals positive for DRB1*1201 have higher levels
of antibodies (i.e., mean OD) to AMA1 than do individuals
with all other HLA-DRB1 alleles. Since the estimated coeffi-
cient for age and AMA1 mean OD is essentially equal to the
estimated coefficient for DRB1*1201 and AMA1 mean OD,
one can conclude that DRB1*1201-positive individuals who
are under age 15 have the same mean AMA1 OD as do
DRB1*1201-negative individuals who are age 15 or over. How-
ever, those individuals over age 15 and DRB1*1201 positive
have an even greater mean level of antibodies to AMA1.
Individuals positive for DQB1*0501 also have higher levels
of antibodies to AMA1 than do individuals with all other
HLA-DQB1 alleles. A significant association is observed be-
tween levels of antibodies to AMA1 and those to DQB1*0501
in the single-allele analysis but not in the multiallele analysis
(Table 4). The association is not as strong between mean
AMA1 OD and DQB1*0501 (estimated coefficient  0.102,
SE 0.041, P 0.03) as observed with DRB1*1201 (estimated
coefficient  0.177, SE  0.062, P  0.005). In Cameroon,
HLA-DRB1*1201 is observed most frequently (9 of 13) on the
same haplotype with DQB1*0501 (32). On the other hand, in
Cameroon, DQB1*0501 is frequently present on haplotypes
with other DRB1 alleles, i.e., HLA-DRB1*0102/DQB1*0501,
DRB1*1101/DQB1*0501, DRB1*1302/DQB1*0501, DRB1*
1401/DQB1*0501, and DRB1*1001/DQB1*0501 (32). Thus,
the observed increase in levels of antibodies to AMA1 is either
with DRB1*1201 or another gene located closer to the
DRB1*1201 gene than to the DQB1*0501 gene. Because most
DRB1*1201-positive individuals are also DQB1*0501 positive,
as expected, a significant association was observed between
levels of antibodies to AMA1 and the DRB1*1201/DQB1*
0501 haplotype. The estimated coefficient for DRB1*1201
alone (0.177, SE  0.062) is essentially identical to that for the
DRB1*1201/DQB1*0501 haplotype (0.17, SE  0.065).
The multiallele regression model resulted in higher P values
and slightly higher estimates of the SE of the coefficient asso-
ciated with DRB1*1201 than did the single-allele analysis, in
which only DRB1*1201 was considered. This is as expected, in
this case, because DRB1*1201 is the only DRB1 allele that is
associated with higher AMA1 antibody levels. Inclusion of the
six other frequent DRB1 alleles, all of which are not associated
with AMA1 antibody levels and whose presence, because they
are allelic, is negatively associated with DRB1*1201, would
result in an overspecified model. Thus, the multiallele regres-
sion model is a less precise model than the simple single-allele
model with only DRB1*1201 and age. If more than one HLA
allele was associated with an increase in AMA1 antibody level,
this would not be the case.
Additional analyses are supportive of DRB1*1201 being the
only DRB1 allele associated with higher levels of antibodies to
AMA1 in this African population. These analyses included a
multiallele regression approach and a Bayesian optimal subset
analysis done with SSVS with different priors that considered all
subsets (28) of the seven frequent HLA-DRB1 alleles and age.
This analysis was done with the objective of obtaining additional
rather than confirmatory information on associations between the
HLA alleles and antibody level. By the use of the SSVS method,
the subset with the highest posterior probability contained no
variables other than age and DRB1*1201. Thus, we have several
indications that DRB1*1201 and age (15 years versus 15
years) are the two predictors of the higher AMA1 antibody level.
Also, we can be reasonably sure that no other HLA association
was observed for AMA1 antibody level.
No interactions are observed in this study between age and the
HLA alleles for AMA1. However, we point out that this does not
mean, necessarily, that the HLA allele effects are all uniform for
all ages. It may simply be a result of not having sufficient power to
detect any age-dependent HLA effects. However, we might con-
jecture that any existing interactions between age and HLA allele
on OD value are probably quite small.
Since we were not able to collect longitudinal data for the
number of clinical malaria episodes in the study reported here,
the clinical significance of the higher levels of antibodies to
rAMA1 associated with DRB1*1201, if any, is not known. It
should be noted that AMA1 is highly polymorphic, and only one
variant has been analyzed in this study, i.e., rAMA1 from the 7G8
Brazilian strain. AMA1 sequences of Cameroonian isolates have
not been determined. Thus, we do not know how much of the
measured ELISA response may be strain specific and how much
may be directed against conserved epitopes. In the assay em-
ployed, conserved epitopes are seen early during exposure, while
with time, more exposure gives a wider repertoire of antibody
specificity including strain-specific 7G8 epitopes. Thus, while se-
rum from adults might be expected to react with most, if not all,
rAMA1 from other isolates (3D7, D10, and HB3), the magnitude
of the OD might vary among AMA1 variants. We cannot con-
clude, without testing, that the observed effect of HLA-
DRB1*1201 on levels of antibodies to rAMA1 from the 7G8
isolate would extrapolate to the antibody response to rAMA1
molecules from other isolates. Unfortunately, serum is not avail-
able to test additional isolates to resolve this question.
A few individuals in all age groups tested negative for
MSP119-specific antibodies, thus suggesting that restriction
might exist for these moieties. No HLA influence was identi-
fied, however, for response to MSP119. Also, no HLA influence
was identified for levels of antibodies to MSA2. Since our
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analyses tested only for the effect of individual frequent HLA
alleles and haplotypes that were found frequently in the pop-
ulation (i.e., observed in 10% or more of the population), an
association could have been missed if antibody levels are as-
sociated with one of the low-frequency HLA alleles not ana-
lyzed or if a combination of HLA class II alleles influences
antibody levels. Another possibility is that the inability to de-
tect an influence of HLA on antibody level might reflect a
strain-specific response to the recombinant protein tested. The
response to another strain might show an influence. Alterna-
tively, HLA class II alleles may not affect the level of antibody
to these molecules. A study of twins in The Gambia supports a
lack of influence of HLA on antibody response to MSP1 and
MSA2 (22). Although the study reported a strong genetic com-
ponent for antibody responses to MSP142 (MSP119 is included
in MSP142) and MSA2, the genetic influence appeared to be
primarily due to non-HLA genes (22).
In an earlier report, high levels of antibodies to RAP1 and
RAP2 were associated with an HLA class II allele (23). Be-
cause the previously analyzed data set for RAP1 and RAP2
included individuals living in the same household, we have
subsequently reanalyzed the data using only one individual per
household. The results of the reanalysis confirmed the previ-
ously reported associations. Individuals positive for HLA-
DQB1*03 have higher levels of antibodies to RAP1 than do
individuals of all other HLA types (estimated coefficient 
0.077, SE  0.03, P  0.02), and individuals positive for HLA-
DRB1*03011 have higher levels of antibodies to RAP2 than do
individuals of all other HLA types (estimated coefficient 
0.11, SE 0.05, P 0.05). The significant decrease in variance
in RAP1 attributable to the DQB1 alleles is observed only on
combining the two DQB*03 alleles into a supertype as was
done in a previous paper. Therefore, the previously reported
results for RAP1 and RAP2 remain solid following additional
analyses of a sample that includes the original analyzed sub-
jects plus additional individuals from the same population.
Combining the results of the previous and present studies,
higher levels of antibodies to three of five asexual-stage anti-
gens studied are associated with an HLA class II allele. In each
case, the associated HLA allele is different.
Published studies correlate high levels of antibodies to
MSA2 (1, 49), MSP1 (2, 5, 9, 38, 52), RAP1 and RAP2 (21, 45),
and RESA (39) with low parasite densities or lower preva-
lences of anemia and/or fewer clinical episodes of malaria.
Definitive conclusions about the role of high levels of antibod-
ies to AMA1 are not available. The extensive polymorphism of
HLA alleles is generally accepted to have evolved as a result of
selective pressure caused by pathogens with certain HLA types
affording more protection against a given pathogen. If the
above associations between HLA and higher levels of antibod-
ies to AMA1, RAP1, RAP2, and RESA have clinical rele-
vance, then protection from malarial disease would be associ-
ated with several HLA alleles. Thus, not all “immune”
individuals would necessarily share the same HLA alleles or
haplotypes. This situation would provide the population with
some protection against malaria while still allowing population
fitness against other pathogens.
Results of this study have several implications for vaccine de-
velopment. First, no evidence of HLA restriction was found at the
population level for the antibody response to any of the five
recombinant antigens that we have studied. Thus, HLA alleles
commonly found in African populations do not appear to pose a
problem for use of these antigens in a vaccine. Second, everyone
produced antibody at an early age (5 years and older) to all of the
polypeptide antigens. Thus, the polypeptide antigens are broadly
immunogenic at the population level. For MSA2 and MSP1-
190L, individuals had already acquired the maximal level of an-
tibodies by 5 years of age. Finally, antibody levels continued to
increase until 15 years of age for AMA1 and the four MSP119
variants but remained constant thereafter. Although HLA restric-
tion does not appear to be a problem, HLA alleles do influence
levels of antibodies to three of the five malarial antigens that we
have studied. Individuals with DRB1*1201, DQB1*03, and
DRB1*0301 alleles produced higher levels of antibodies to
AMA1, RAP1, and RAP2, respectively.
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